Importantly, through animal models and patient-derived organoid models, we demonstrated that targeting RAD51B downstream signaling with EZH2i re-induces functional ERα protein expression in ERα-negative breast cancer, thereby rendering tumors targetable by tamoxifen. The gene discussed is RAD51B; the disease is breast carcinoma.